Regeneration of the heart in diabetes by selective copper chelation

Garth J S Cooper1, Anthony R J Phillips, Soon Y Choong

  • 1Level 4, Thomas Building, School of Biological Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand. g.cooper@auckland.ac.nz

Diabetes
|August 28, 2004
PubMed

Insights

Copper chelation therapy using trientine shows promise for treating heart disease in diabetes. This treatment improved heart function and structure in diabetic rats and humans without affecting blood glucose levels.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Toxicology

Background:

  • Heart disease is a leading cause of mortality in diabetic patients.
  • The role of transition metal metabolism, specifically copper, in diabetic heart disease is not fully understood.
  • Previous research has explored altered systemic regulation of transition metals in diabetes.

Purpose of the Study:

  • To investigate if altered transition metal metabolism contributes to heart disease in diabetes.
  • To determine if metal chelation therapy can reverse cardiac complications in diabetes.
  • To explore the efficacy of copper-selective chelation in managing diabetic cardiomyopathy.

Main Methods:

  • Administration of the copper-selective chelator trientine to rats with streptozotocin-induced diabetes.
  • Analysis of urinary copper excretion and identification of copper-trientine complexes.
  • Assessment of cardiac function, cardiomyocyte structure, and left ventricular collagen and beta(1) integrin levels in treated diabetic rats.
  • Evaluation of trientine's effects on copper excretion and left ventricular mass in human patients with type 2 diabetes.

Main Results:

  • Trientin administration increased urinary copper excretion in diabetic rats, forming a detectable copper-trientine complex.
  • In diabetic rats with heart failure, trientine therapy significantly alleviated cardiac dysfunction and improved cardiomyocyte structure.
  • Trientin treatment reversed elevated left ventricular collagen and beta(1) integrin in diabetic rats.
  • In humans with type 2 diabetes, oral trientine increased copper excretion and significantly reduced elevated left ventricular mass.

Conclusions:

  • Elevated levels of loosely bound copper contribute to cardiac damage in diabetes.
  • Selective copper chelation with trientine is a potential therapeutic strategy for diabetic heart disease.
  • Trientin therapy can improve cardiac structure and function in diabetes independently of blood glucose control.